Bradford D. Dahms - 06 Oct 2021 Form 3 Insider Report for Theseus Pharmaceuticals, Inc.

Role
Chief Financial Officer
Signature
/s/ Bradford Dahms
Issuer symbol
N/A
Transactions as of
06 Oct 2021
Net transactions value
$0
Form type
3
Filing time
06 Oct 2021, 19:00:49 UTC
Next filing
22 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding THRX Stock Option (right to buy) 06 Oct 2021 Common Stock 332,114 $4.03 Direct F1
holding THRX Stock Option (right to buy) 06 Oct 2021 Common Stock 23,885 $9.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on May 25, 2022 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer
F2 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on August 27, 2022 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.